Bailard, Inc. Lyell Immunopharma, Inc. Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
114Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$11.5 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$8.6 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$8.6 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$7.69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$5.74 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $141M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...